ClinicalTrials.gg
CompletedNCT00489554Updated Jan 13, 2020Results posted

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age

A Phase 3 interventional study of Synflorix and Infanrix hexa in Infections, Streptococcal and Streptococcus Pneumoniae Vaccines, sponsored by GlaxoSmithKline. Completed at 2 sites in Mexico. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-13.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Non-randomized
Ages
6 Weeks to 12 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies testing PHiD-CV vaccine in Streptococcal Infections — none open to participants now, none under way, none of them phase 3. PHiD-CV vaccine · Streptococcal Infections.

Enrollment
21st of 25
230 · median 360
Started
2007
with 3 others
Phase 3
24 of 25
none open now
Registered
3rd of 25
by date
Lead sponsor
25 of 25
GlaxoSmithKline

Among the 25 studies testing PHiD-CV vaccine in Streptococcal Infections, this one is the 21st largest by enrollment, is one of 4 that started in 2007, is one of 24 in phase 3, and was the 3rd registered.

Streptococcal Infections

147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.

Browse Streptococcal Infections studies →

Open to participants now

None of the 25 studies testing PHiD-CV vaccine in Streptococcal Infections is open now. The open studies under Streptococcal Infections, anywhere →

About PHiD-CV vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 10 Streptococcal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies testing PHiD-CV vaccine in Streptococcal Infections as a file.
02

Study summary

The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of Mexican infants with pneumococcal conjugate vaccine GSK 1024850A co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined vaccine (Infanrix hexa) and rotavirus vaccine (Rotarix) in children during the first 6 months of age.

Read the detailed description

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

03

Conditions studied

  • Infections, Streptococcal
  • Streptococcus Pneumoniae Vaccines

Keywords

  • Primary vaccination
  • Safety
  • Pneumococcal vaccine.
  • Pneumococcal disease
  • Immunogenicity
04

Who can participate

Ages eligible
6 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between and including 6-12 weeks of age at the time of the first vaccination.
  • Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • Written obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Born after a gestation period of 36 to 42 weeks inclusive.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccines and ending 7 days after dose 1 and dose 2 and one month after dose 3.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Chronic administration (defined as more than 14 days) of or other immune-modifying drugs since birth.
  • A family history of congenital or hereditary immunodeficiency.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • Previous vaccination against diphtheria, tetanus, pertussis, polio, , Haemophilus influenzae type b, rotavirus and/or Streptococcus pneumoniae; with the exception of vaccines where the first dose may be given at birth within the first two weeks of life according to national recommendations (e.g. Hepatitis B and BCG).
  • History of, or intercurrent, diphtheria, tetanus, pertussis, polio, hepatitis B and Haemophilus influenzae type b disease.
  • Gastroenteritis within 7 days preceding the study vaccine administration (warrants deferral of the vaccination).
  • Any history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal (GI) tract, intussusception (IS) or other medical condition determined to be serious by the investigator.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • History of any neurological disorders or seizures.
  • Major congenital defects or serious chronic illness.
  • Acute disease at the time of enrolment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    Synflorix Vaccine Group

    Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.

    Biological: Synflorix · Biological: Infanrix hexa · Biological: Rotarix

Interventions

06

What researchers measure

Primary outcomes

  1. Antibody Concentrations Against Pneumococcal Vaccine Serotypes

    Concentrations were expressed as geometric mean concentration (GMC). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

    Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

  2. Antibody Concentrations Against Protein D

    Concentrations were given as geometric mean concentration (GMC) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter.

    Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

Secondary outcomes

  1. Opsonophagocytic Titer Against Pneumococcal Vaccine Serotypes

    The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

    Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

  2. Number of Subjects With Anti-pneumococcal Vaccine Serotypes Antibody Concentrations Greater Than or Equal to 0.2 Microgram Per Milliliter

    The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

    Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

  3. Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes

    Antibody concentrations were expressed as Geometric Mean Concentrations against pneumococcal cross-reactive serotypes 6A and 19A.

    Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

  4. Opsonophagocytic Titer Against Pneumococcal Cross-reactive Serotypes

    The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

    Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

  5. Number of Subjects Seropositive Against Vaccine Pneumococcal Serotypes

    Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

    Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

  6. Number of Subjects Seropositive for Opsonic Titer Against Vaccine Pneumococcal Serotypes

    Seropositivity was defined as an opsonic titer greater than or equal to 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

    Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

  7. Number of Subjects Seropositive Against Cross-reactive Pneumococcal Serotypes

    Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

    Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

  8. Number of Subjects Seropositive for Opsonic Titer Against Cross-reactive Pneumococcal Serotypes

    Seropositivity was defined as anti-pneumococcal antibody opsonic titer greater than or equal to 8. The vaccine pneumococcal cross-reactive serotypes assessed include 6A and 19A.

    Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

  9. Number of Subjects Seropositive for Anti-Protein D Antibodies

    Seropositivity was defined as antibody concentration greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter.

    Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5

  10. Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)

    Grade 3 redness and swelling was \> 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful. Any was occurrence of any local symptom regardless of grade and whatever the number of injections.

    Time frame: Within 4 days following any vaccine dose

  11. Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs

    Any fever was defined as axillary temperature ≥ 37.5 degree centigrade (°C), grade 3 fever was axillary temperature \> 39.5°C. Grade 3 drowsiness, irritability, and loss of appetite was general symptom which prevented normal everyday activities. Grade 3 diarrhea was ≥ 6 looser than normal stools/day and Grade 3 vomiting was ≥ 3 episodes of vomiting/day. Related was solicited general symptom considered by the investigator to have a causal relationship to study vaccination.

    Time frame: Within 4 days following any vaccine dose

  12. Number of Subjects Reporting Any Unsolicited AEs

    Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Time frame: Within 31 days after any vaccine dose

  13. Number of Subjects Reporting Any Serious Adverse Events (SAEs)

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

    Time frame: Up to Month 5

07

Results

Posted May 10, 2012

Participant flow

Participant flow — Overall Study
MilestoneSynflorix Vaccine Group
Started230
Completed226
Not completed4
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryAntibody Concentrations Against Pneumococcal Vaccine Serotypes

Concentrations were expressed as geometric mean concentration (GMC). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

Time frame:
One month after the administration of the 3rd vaccine dose i.e. Month 5
Reported as:
Geometric mean · microgram per milliliter
Antibody Concentrations Against Pneumococcal Vaccine Serotypes
microgram per milliliterSynflorix Vaccine Group
Anti-1 antibody (N=219)2.13 (1.94 to 2.34)
Anti-4 antibody (N=218)3.04 (2.77 to 3.34)
Anti-5 antibody (N=218)3.24 (2.97 to 3.53)
Anti-6B antibody (N=218)1.32 (1.14 to 1.54)
Anti-7F antibody (N=218)3.72 (3.40 to 4.07)
Anti-9V antibody (N=218)3.71 (3.37 to 4.09)
Anti-14 antibody (N=218)5.27 (4.66 to 5.96)
Anti-18C antibody (N=219)6.05 (5.30 to 6.89)
Anti-19F antibody (N=219)5.49 (4.88 to 6.17)
Anti-23F antibody (N=218)2.00 (1.70 to 2.35)
PrimaryAntibody Concentrations Against Protein D

Concentrations were given as geometric mean concentration (GMC) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter.

Time frame:
One month after the administration of the 3rd vaccine dose i.e. Month 5
Reported as:
Geometric mean · ELISA units per milliliter
Antibody Concentrations Against Protein D
ELISA units per milliliterSynflorix Vaccine Group
Antibody Concentrations Against Protein D2923.2 (2588.6 to 3301.1)
SecondaryOpsonophagocytic Titer Against Pneumococcal Vaccine Serotypes

The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

Time frame:
One month after the administration of the 3rd vaccine dose i.e. Month 5
Reported as:
Geometric mean · titer
Opsonophagocytic Titer Against Pneumococcal Vaccine Serotypes
titerSynflorix Vaccine Group
Opsono-1 titer (N=97)94.1 (68.2 to 130.0)
Opsono-4 titer (N=97)670.8 (516.1 to 871.7)
Opsono-5 titer (N=94)148.8 (120.6 to 183.6)
Opsono-6B titer (N=96)345.4 (205.5 to 580.4)
Opsono-7F titer (N=96)4435.4 (3635.9 to 5410.7)
Opsono-9V titer (N=96)1186.1 (955.9 to 1471.7)
Opsono-14 titer (N=94)1168.3 (907.4 to 1504.2)
Opsono-18C titer (N=94)222.9 (157.9 to 314.9)
Opsono-19F titer (N=92)589.2 (441.9 to 785.5)
Opsono-23F titer (N=95)1876.3 (1325.4 to 2656.0)
SecondaryNumber of Subjects With Anti-pneumococcal Vaccine Serotypes Antibody Concentrations Greater Than or Equal to 0.2 Microgram Per Milliliter

The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

Time frame:
One month after the administration of the 3rd vaccine dose i.e. Month 5
Reported as:
Number · subjects
Number of Subjects With Anti-pneumococcal Vaccine Serotypes Antibody Concentrations Greater Than or Equal to 0.2 Microgram Per Milliliter
subjectsSynflorix Vaccine Group
Anti-1 antibody (N=219)219
Anti-4 antibody (N=218)218
Anti-5 antibody (N=218)218
Anti-6B antibody (N=218)203
Anti-7F antibody (N=218)218
Anti-9V antibody (N=218)218
Anti-14 antibody (N=218)216
Anti-18C antibody (N=219)218
Anti-19F antibody (N=219)217
Anti-23F antibody (N=218)207
SecondaryAntibody Concentrations Against Pneumococcal Cross-reactive Serotypes

Antibody concentrations were expressed as Geometric Mean Concentrations against pneumococcal cross-reactive serotypes 6A and 19A.

Time frame:
One month after the administration of the 3rd vaccine dose i.e. Month 5
Reported as:
Geometric mean · microgram per milliliter
Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes
microgram per milliliterSynflorix Vaccine Group
Anti-6A antibody0.28 (0.24 to 0.34)
Anti-19A antibody0.26 (0.22 to 0.31)
SecondaryOpsonophagocytic Titer Against Pneumococcal Cross-reactive Serotypes

The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

Time frame:
One month after the administration of the 3rd vaccine dose i.e. Month 5
Reported as:
Geometric mean · titer
Opsonophagocytic Titer Against Pneumococcal Cross-reactive Serotypes
titerSynflorix Vaccine Group
Opsono-6A titer (N=91)159.2 (98.8 to 256.4)
Opsono-19A titer (N=81)11.6 (7.3 to 18.4)
SecondaryNumber of Subjects Seropositive Against Vaccine Pneumococcal Serotypes

Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

Time frame:
One month after the administration of the 3rd vaccine dose i.e. Month 5
Reported as:
Number · subjects
Number of Subjects Seropositive Against Vaccine Pneumococcal Serotypes
subjectsSynflorix Vaccine Group
Anti-1 antibody (N=219)219
Anti-4 antibody (N=218)218
Anti-5 antibody (N=218)218
Anti-6B antibody (N=218)212
Anti-7F antibody (N=218)218
Anti-9V antibody (N=218)218
Anti-14 antibody (N=218)218
Anti-18C antibody (N=219)218
Anti-19F antibody (N=219)219
Anti-23F antibody (N=218)212
SecondaryNumber of Subjects Seropositive for Opsonic Titer Against Vaccine Pneumococcal Serotypes

Seropositivity was defined as an opsonic titer greater than or equal to 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

Time frame:
One month after the administration of the 3rd vaccine dose i.e. Month 5
Reported as:
Number · subjects
Number of Subjects Seropositive for Opsonic Titer Against Vaccine Pneumococcal Serotypes
subjectsSynflorix Vaccine Group
Opsono-1 titer (N=97)83
Opsono-4 titer (N=97)93
Opsono-5 titer (N=94)93
Opsono-6B titer (N=96)76
Opsono-7F titer (N=96)96
Opsono-9V titer (N=96)96
Opsono-14 titer (N=94)93
Opsono-18C titer (N=94)91
Opsono-19F titer (N=92)90
Opsono-23F titer (N=95)90
SecondaryNumber of Subjects Seropositive Against Cross-reactive Pneumococcal Serotypes

Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

Time frame:
One month after the administration of the 3rd vaccine dose i.e. Month 5
Reported as:
Number · subjects
Number of Subjects Seropositive Against Cross-reactive Pneumococcal Serotypes
subjectsSynflorix Vaccine Group
Anti-6A antibody203
Anti-19A antibody198
SecondaryNumber of Subjects Seropositive for Opsonic Titer Against Cross-reactive Pneumococcal Serotypes

Seropositivity was defined as anti-pneumococcal antibody opsonic titer greater than or equal to 8. The vaccine pneumococcal cross-reactive serotypes assessed include 6A and 19A.

Time frame:
One month after the administration of the 3rd vaccine dose i.e. Month 5
Reported as:
Number · subjects
Number of Subjects Seropositive for Opsonic Titer Against Cross-reactive Pneumococcal Serotypes
subjectsSynflorix Vaccine Group
Opsono-6A titer (N=91)69
Opsono-19A titer (N=81)19
SecondaryNumber of Subjects Seropositive for Anti-Protein D Antibodies

Seropositivity was defined as antibody concentration greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter.

Time frame:
One month after the administration of the 3rd vaccine dose i.e. Month 5
Reported as:
Number · subjects
Number of Subjects Seropositive for Anti-Protein D Antibodies
subjectsSynflorix Vaccine Group
Number of Subjects Seropositive for Anti-Protein D Antibodies219
SecondaryNumber of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)

Grade 3 redness and swelling was \> 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful. Any was occurrence of any local symptom regardless of grade and whatever the number of injections.

Time frame:
Within 4 days following any vaccine dose
Reported as:
Number · subjects
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
subjectsSynflorix Vaccine Group
Any pain196
Grade 3 pain80
Any redness91
Grade 3 redness0
Any swelling178
Grade 3 swelling10
SecondaryNumber of Subjects Reporting Any, Grade 3 and Related Solicited General AEs

Any fever was defined as axillary temperature ≥ 37.5 degree centigrade (°C), grade 3 fever was axillary temperature \> 39.5°C. Grade 3 drowsiness, irritability, and loss of appetite was general symptom which prevented normal everyday activities. Grade 3 diarrhea was ≥ 6 looser than normal stools/day and Grade 3 vomiting was ≥ 3 episodes of vomiting/day. Related was solicited general symptom considered by the investigator to have a causal relationship to study vaccination.

Time frame:
Within 4 days following any vaccine dose
Reported as:
Number · subjects
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
subjectsSynflorix Vaccine Group
Any diarrhea55
Grade 3 diarrhea5
Related diarrhea55
Any drowsiness156
Grade 3 drowsiness7
Related drowsiness153
Any fever147
Grade 3 fever0
Related fever147
Any irritability198
Grade 3 irritability21
Related irritability196
Any loss of appetite113
Grade 3 loss of appetite1
Related loss of appetite111
Any vomiting56
Grade 3 vomiting7
Related vomiting56
SecondaryNumber of Subjects Reporting Any Unsolicited AEs

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Time frame:
Within 31 days after any vaccine dose
Reported as:
Number · subjects
Number of Subjects Reporting Any Unsolicited AEs
subjectsSynflorix Vaccine Group
Number of Subjects Reporting Any Unsolicited AEs174
SecondaryNumber of Subjects Reporting Any Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

Time frame:
Up to Month 5
Reported as:
Number · subjects
Number of Subjects Reporting Any Serious Adverse Events (SAEs)
subjectsSynflorix Vaccine Group
Number of Subjects Reporting Any Serious Adverse Events (SAEs)15

Adverse events

Collected over Serious adverse events were assessed up to month 5. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 4 day and 31 day post vaccination period respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Synflorix Vaccine Group—15/230 (6.5%)229/230 (99.6%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventSynflorix Vaccine Group
BronchopneumoniaInfections and infestations6/230
BronchiolitisInfections and infestations4/230
DehydrationMetabolism and nutrition disorders2/230
GastroenteritisInfections and infestations2/230
NasopharyngitisInfections and infestations2/230
Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders1/230
Cerebral infarctionNervous system disorders1/230
ConjunctivitisEye disorders1/230
ConvulsionNervous system disorders1/230
HerpanginaInfections and infestations1/230
Most frequent other events
Showing 10 of 16
Most frequent other events
EventSynflorix Vaccine Group
IrritabilityGeneral disorders198/230
PainGeneral disorders196/230
SwellingGeneral disorders178/230
DrowsinessGeneral disorders156/230
FeverGeneral disorders147/230
NasopharyngitisGeneral disorders123/230
Loss of appetiteGeneral disorders113/230
RednessGeneral disorders91/230
VomitingGeneral disorders56/230
DiarrheaGeneral disorders55/230

Baseline characteristics

Age, Continuous
Age, Continuous(weeks)Synflorix Vaccine Group
Mean8.2 ± 1.63
Sex: Female, Male
Sex: Female, Male(Participants)Synflorix Vaccine Group
Female123
Male107
08

Study locations

2 sites
  • GSK Investigational Site
    Mexico city, 14000, Mexico
  • GSK Investigational Site
    Mexico, 14000, Mexico
09

References and documents

Publications

  • Ruiz-Palacios G et al. Immunogenicity, safety and reactogenicity of the new 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) in Mexican infants. Abstract presented at the XIII Congreso Latinoamericano de Infectología Pediátrica (SLIPE). Guayaquil, Ecuador, 12-15 August 2009.
  • Ruiz-Palacios GM, Guerrero ML, Hernandez-Delgado L, Lavalle-Villalobos A, Casas-Munoz A, Cervantes-Apolinar Y, Moreira M, Schuerman L. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants. Hum Vaccin. 2011 Nov;7(11):1137-45. doi: 10.4161/hv.7.11.17984. Epub 2011 Nov 1. PubMed 22048109 ↗
  • Schuerman L et al. Population variability in antibody responses following pneumococcal conjugate vaccination: experience with the non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.
  • Schuerman L et al. Population variability of opsonophagocytic activity following 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate (PHiD-CV) vaccination more limited than antibody responses. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.
  • Silfverdal SA, Coremans V, Francois N, Borys D, Cleerbout J. Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Expert Rev Vaccines. 2017 Feb;16(2):109-121. doi: 10.1586/14760584.2016.1164044. Epub 2016 Sep 30. PubMed 26954689 ↗

Individual participant data

Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below).

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2007 to primary completion in Mar 2008, 8 months.

Results were first posted in May 2012, 4 years 1 month after primary completion.

Of 28 industry-sponsored phase 3 interventional studies under Streptococcal Infections, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 13. This study's 8 months is below that.

Counting every sponsor, half of 29 studies reached it within 10 months; a quarter within 8 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2007
First posted
Jun 21, 2007
StartActual
Jul 3, 2007
Primary completionActual
Mar 31, 2008
CompletionActual
Mar 31, 2008
Results first posted
May 10, 2012
Last update
Jan 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00489554
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 21, 2007
Start date
Jul 3, 2007
Primary completion
Mar 31, 2008
Completion
Mar 31, 2008
Results posted
May 10, 2012
Last update
Jan 13, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PHiD-CV vaccine · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · RIX4414 vaccine

Start the discussion